Cargando…
Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that govern...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875321/ https://www.ncbi.nlm.nih.gov/pubmed/35214080 http://dx.doi.org/10.3390/pharmaceutics14020348 |
_version_ | 1784657885459906560 |
---|---|
author | Hwang, Jimin Mros, Sonya Gamble, Allan B. Tyndall, Joel D. A. McDowell, Arlene |
author_facet | Hwang, Jimin Mros, Sonya Gamble, Allan B. Tyndall, Joel D. A. McDowell, Arlene |
author_sort | Hwang, Jimin |
collection | PubMed |
description | Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that governs biological interactions, the absence of well-defined size control technology has hampered the investigation of optimal nanoparticle size for targeting bacterial cells. Previously, we identified a lead antichlamydial compound JO146 against the high temperature requirement A (HtrA) protease, a promising antibacterial target involved in protein quality control and virulence. Here, we reveal that JO146 was active against Helicobacter pylori with a minimum bactericidal concentration of 18.8–75.2 µg/mL. Microfluidic technology using a design of experiments approach was utilized to formulate JO146-loaded poly(lactic-co-glycolic) acid nanoparticles and explore the effect of the nanoparticle size on drug delivery. JO146-loaded nanoparticles of three different sizes (90, 150, and 220 nm) were formulated with uniform particle size distribution and drug encapsulation efficiency of up to 25%. In in vitro microdilution inhibition assays, 90 nm nanoparticles improved the minimum bactericidal concentration of JO146 two-fold against H. pylori compared to the free drug alone, highlighting that controlled engineering of nanoparticle size is important in drug delivery optimization. |
format | Online Article Text |
id | pubmed-8875321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88753212022-02-26 Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles Hwang, Jimin Mros, Sonya Gamble, Allan B. Tyndall, Joel D. A. McDowell, Arlene Pharmaceutics Article Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that governs biological interactions, the absence of well-defined size control technology has hampered the investigation of optimal nanoparticle size for targeting bacterial cells. Previously, we identified a lead antichlamydial compound JO146 against the high temperature requirement A (HtrA) protease, a promising antibacterial target involved in protein quality control and virulence. Here, we reveal that JO146 was active against Helicobacter pylori with a minimum bactericidal concentration of 18.8–75.2 µg/mL. Microfluidic technology using a design of experiments approach was utilized to formulate JO146-loaded poly(lactic-co-glycolic) acid nanoparticles and explore the effect of the nanoparticle size on drug delivery. JO146-loaded nanoparticles of three different sizes (90, 150, and 220 nm) were formulated with uniform particle size distribution and drug encapsulation efficiency of up to 25%. In in vitro microdilution inhibition assays, 90 nm nanoparticles improved the minimum bactericidal concentration of JO146 two-fold against H. pylori compared to the free drug alone, highlighting that controlled engineering of nanoparticle size is important in drug delivery optimization. MDPI 2022-02-01 /pmc/articles/PMC8875321/ /pubmed/35214080 http://dx.doi.org/10.3390/pharmaceutics14020348 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hwang, Jimin Mros, Sonya Gamble, Allan B. Tyndall, Joel D. A. McDowell, Arlene Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles |
title | Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles |
title_full | Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles |
title_fullStr | Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles |
title_full_unstemmed | Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles |
title_short | Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles |
title_sort | improving antibacterial activity of a htra protease inhibitor jo146 against helicobacter pylori: a novel approach using microfluidics-engineered plga nanoparticles |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875321/ https://www.ncbi.nlm.nih.gov/pubmed/35214080 http://dx.doi.org/10.3390/pharmaceutics14020348 |
work_keys_str_mv | AT hwangjimin improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles AT mrossonya improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles AT gambleallanb improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles AT tyndalljoelda improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles AT mcdowellarlene improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles |